CHARLOTTESVILLE, Va., June 01, 2016 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (OTCQX:DFFN), a clinical stage
biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management
will be presenting at the JMP Securities Life Sciences Conference to be held June 21- 22, 2016 in New York, NY.
David Kalergis, Chairman and Chief Executive Officer of Diffusion, is scheduled to present on Tuesday, June 21,
2016 at 2:30 PM ET.
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting
the Investor Relations section of Diffusion's website, www.diffusionpharma.com.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by
improving the effectiveness of current standard-of-care treatments including radiation therapy and chemotherapy. Diffusion is
developing its lead drug, trans sodium crocetinate (TSC), for use in the many cancer types in which tumor hypoxia (oxygen
deprivation) is known to diminish the effectiveness of current treatments. TSC targets the cancer’s hypoxic
micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects
of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects.
A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed
glioblastoma multiforme (GBM). This open label, historically controlled study demonstrated a favorable safety and efficacy
profile for TSC combined with standard of care. The U.S. Food and Drug Administration has agreed upon the design of a Phase 3
trial in newly diagnosed GBM. Additional planned studies, subject to receipt of necessary financing, include the Phase 2
trial in pancreatic cancer and a study in brain metastases. Due to its novel mechanism of action, TSC has safely re-oxygenated a
range of tumor types in our preclinical and clinical studies. The Company believes its therapeutic potential is not limited to
specific tumors, thereby making it potentially useful to improve standard-of-care treatments of other life-threatening cancers. We
also believe that TSC has potential application in other indications involving hypoxia, such as stroke and neurodegenerative
diseases.
Diffusion Pharmaceuticals Contacts David Kalergis Chief Executive Officer Diffusion Pharmaceuticals Inc. (434) 220-0718 dkalergis@diffusionpharma.com Stephanie Carrington ICR Inc. (646) 277-1282 Stephanie.Carrington@icrinc.com
